Title : Plasma anti-FXa concentration after continuous intravenous infusion and subcutaneous dosing of enoxaparin for thromboprophylaxis in critically ill patients. A randomized clinical trial.

Pub. Date : 2017 Oct

PMID : 28846877






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Plasma anti-FXa concentration after continuous intravenous infusion and subcutaneous dosing of enoxaparin for thromboprophylaxis in critically ill patients. Enoxaparin coagulation factor X Homo sapiens
2 CONCLUSIONS: Continuous infusion of enoxaparin led to lower anti-FXa Cmax24h than standard SCB administration. Enoxaparin coagulation factor X Homo sapiens